MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.
The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.
MannKind Corp. director Michael A. Friedman exercised options to acquire 30,000 common shares at an exercise price of $1.10 per share on November 17, 2026. That day, 8,109 shares were delivered or withheld for payment of exercise price or tax liability. The reported option balance following the exercise was 0. The filing reports no Rule 10b5-1 plan.
MannKind Corp (MNKD) is the issuer whose common stock State Street Corporation reports beneficially owning 15,096,712 shares as of September 30, 2026, representing 4.7% of the class. State Street reports shared voting power over 14,316,800 shares and shared dispositive power over 15,096,712 shares, with zero sole voting or dispositive power.
MannKind reported third-quarter 2026 revenue of $101.9 million, compared with $82.1 million a year earlier, while net results shifted to a $23.2 million loss from $8.0 million of income. Commercial product sales were $45.0 million versus $22.3 million; royalties were $37.5 million versus $33.3 million, while collaboration and services revenue was $19.4 million versus $26.5 million.
For the first nine months, revenue was $301.4 million versus $237.0 million, and net loss was $58.9 million versus net income of $21.8 million. Operating activities used $58.3 million in cash, compared with $26.2 million provided a year earlier. At September 30, cash and equivalents were $41.3 million, short-term investments were $55.3 million and total debt was $319.4 million.
FDA approval of Furoscix ReadyFlow occurred July 23, 2026, resulting in an approximately $44.8 million payout under CVR Milestone 1. For Milestone 2, management did not expect a payout as of September 30; the milestone requires at least $110.0 million of worldwide Furoscix sales in a trailing 12-month period ending on or before December 31, 2026.
MannKind Corporation reported third-quarter 2026 revenue of $101.9 million, up 24% from $82.1 million a year earlier; commercial product sales were $45.0 million, up 102%. GAAP results were a net loss of $23.2 million, versus $8.0 million net income in Q3 2025. Selling, general and administrative expense rose 111% to $61.4 million, mainly reflecting Furoscix promotion, expanded field teams and launch costs.
Furoscix ReadyFlow was approved and shipments began in mid-September; it represented approximately 75% of Furoscix shipments by late October. Afrezza’s pediatric launch coincided with an approximately 80% increase in average monthly new-to-brand prescriptions in Q3 versus Q2 2026. MannKind reported positive Phase 1b INFLO-1 results for nintedanib DPI, and its global Phase 2 trial is underway.
Cash, cash equivalents and investments totaled $96.6 million as of September 30, 2026. For ralinepag DPI, formulation work was complete, United Therapeutics plans to pursue clinical development, and MannKind anticipates earning $15 million in milestone payments in 2027.
MannKind Corp. director Steven B. Binder sold 39,051 shares of common stock on September 25, 2026, at a weighted average price of $3.29 per share. The sale was made under a Rule 10b5-1 plan established December 2, 2025; Binder directly held 713,258 shares after the transaction.
MannKind Corporation director Steven Binder filed a notice proposing to sell 39,051 common shares, with an aggregate market value of $128,477.79 and an approximate sale date of September 25, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are listed as acquired from the issuer through performance stock units on July 15, 2026. The notice also lists three prior sales identified as 10b5-1 sales: 33,558 shares on September 10, 39,051 shares on August 7, and 52,485 shares on July 17, 2026.
MANNKIND CORP (MNKD) director Steven B. Binder reported selling 33,558 shares$3.81 per share752,309 shares
MannKind Corporation director Steven Binder reported a proposed sale of 33,558 common shares, with an approximate sale date of September 10, 2026, and an aggregate market value of $132,218.52. The shares were acquired from the issuer as restricted stock units on July 15, 2026. Two earlier sales are labeled 10b5-1 sales: 52,485 shares on July 17, 2026, for gross proceeds of $212,837.17, and 39,051 shares on August 7, 2026, for $158,562.68. The reported plan adoption date is December 2, 2025.
MannKind Corporation (MNKD) reported that on August 21, 2026 it filed a prospectus supplement to its automatic shelf registration statement on Form S-3 (Registration No. 333-285286) with the SEC. On the same date, MannKind furnished an opinion of Cooley LLP regarding the legality of the issuance and sale of the common stock described in that prospectus supplement, included as Exhibit 5.1, together with Cooley LLP’s related consent as Exhibit 23.1.
MannKind Corporation (MNKD) has filed a prospectus supplement registering for resale up to 12,853,470 shares of common stock by existing selling stockholders. This total includes 10,440,838 issued shares and 2,412,632 shares issuable upon exercise of outstanding pre-funded warrants from a July 24, 2026 private placement.
The company sold the private placement securities at $3.89 per common share and $3.88 per pre-funded warrant, with each pre-funded warrant carrying a $0.01 exercise price and no expiration until exercised, subject to a beneficial ownership limitation not to exceed 19.99%. MannKind will not receive any proceeds from the resale of these shares, though it is paying the registration and related offering expenses.
The selling stockholders may dispose of shares through various methods, including market and negotiated transactions, and may use underwriters, broker-dealers or agents. MannKind’s common stock trades on the Nasdaq Global Market under the symbol MNKD; the last reported sale price was $4.26 per share on August 20, 2026. Shares outstanding were 321,544,484 as of August 14, 2026, a baseline figure distinct from the shares registered for resale.